UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Microbiome

Understanding the Role of the Gut Microbiome in NAFLD

NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.

Read More

A recap of the Microbiome & Probiotics Series: Europe

The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.

Read More

Presentation slides from the 6th Microbiome R&D & Business Collaboration Forum

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.

Read More

Increasing plant protein digestion in an in vitro model

Population increases and patterns of consumption will put pressure on animal protein supply and price over the coming decades. Plant proteins are a viable alternative, but have a lower digestibility then animal proteins.

Read More

Microbiome R&D & Business Collaboration Forum presentation slides

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides from Karoline Faust, Dirk Hadrich, Lesley Hoyles & Jos Seegers available.

Read More

FMT-based discovery: from platform to product

Fecal microbiota transplant (FMT) is probably the microbiome based therapy that has received the most media attention. It seems journalists love to talk about poo.

This has given momentum to research in the field. As the amount of trial data and fear of antibiotic resistance grows, FMT is now a much more common treatment for conditions like clostridioides difficile infection (CDI).

Read More

The Skin Microbiome & Cosmeceuticals Congress presentation slides

Following the Skin Microbiome & Cosmeceuticals Congress: Europe, we have made the following presentation slides from Richard Andrews, Ingmar Claes, Marie Drago & Maya Ivanjesku available.

Read More

The top 4 challenges for microbiome companies – NIZO

Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive